85 related articles for article (PubMed ID: 21130409)
1. Targeting DNA repair pathways in AML.
D'Andrea AD
Best Pract Res Clin Haematol; 2010 Dec; 23(4):469-73. PubMed ID: 21130409
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal instability syndromes are sensitive to poly ADP-ribose polymerase inhibitors.
Gaymes TJ; Shall S; Farzaneh F; Mufti GJ
Haematologica; 2008 Dec; 93(12):1886-9. PubMed ID: 18838476
[TBL] [Abstract][Full Text] [Related]
3. Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Helleday T
Curr Opin Oncol; 2013 Nov; 25(6):609-14. PubMed ID: 24097104
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
5. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Lewis C; Low JA
Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
[TBL] [Abstract][Full Text] [Related]
6. PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Fritz C; Portwood SM; Przespolewski A; Wang ES
Blood Rev; 2021 Jan; 45():100696. PubMed ID: 32482307
[TBL] [Abstract][Full Text] [Related]
7. Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders.
Faraoni I; Giansanti M; Voso MT; Lo-Coco F; Graziani G
Biochem Pharmacol; 2019 Sep; 167():133-148. PubMed ID: 31028744
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of poly(ADP-ribose) polymerase in cancer.
Plummer ER
Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
[TBL] [Abstract][Full Text] [Related]
9. An Achilles' heel for breast cancer?
Caldecott KW; Chalmers A
Nat Struct Mol Biol; 2005 May; 12(5):387-8. PubMed ID: 15870726
[No Abstract] [Full Text] [Related]
10. Poly(ADP-ribose) polymerase inhibitors as potential chemotherapeutic agents.
Bryant HE; Helleday T
Biochem Soc Trans; 2004 Dec; 32(Pt 6):959-61. PubMed ID: 15506935
[TBL] [Abstract][Full Text] [Related]
11. [PARP inhibitors for cancer therapy].
Saito H; Miki Y
Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
[TBL] [Abstract][Full Text] [Related]
12. Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1.
Veuger SJ; Curtin NJ; Richardson CJ; Smith GC; Durkacz BW
Cancer Res; 2003 Sep; 63(18):6008-15. PubMed ID: 14522929
[TBL] [Abstract][Full Text] [Related]
13. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
14. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract][Full Text] [Related]
15. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
16. Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
Kalev P; Simicek M; Vazquez I; Munck S; Chen L; Soin T; Danda N; Chen W; Sablina A
Cancer Res; 2012 Dec; 72(24):6414-24. PubMed ID: 23087057
[TBL] [Abstract][Full Text] [Related]
17. In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells.
Le TV; Suh JH; Kim N; Park HJ
Bioorg Med Chem Lett; 2013 May; 23(9):2642-6. PubMed ID: 23522835
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in breast cancer.
Telli ML; Ford JM
Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
[TBL] [Abstract][Full Text] [Related]
19. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
20. The Role of DNA Repair Pathways in AML Chemosensitivity.
Pearsall EA; Lincz LF; Skelding KA
Curr Drug Targets; 2018; 19(10):1205-1219. PubMed ID: 29318968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
